Europe — EMA

Inlyta (Axitinib)

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor classified as an antineoplastic agent and presented as 1 mg, 2 mg, and 5 mg oral tablets.

Axitinib

Request sourcing

Pack/s

What is Axitinib?

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor classified as an antineoplastic agent and presented as 1 mg, 2 mg, and 5 mg oral tablets. It targets vascular endothelial growth factor receptors to inhibit angiogenesis and is indicated for the treatment of metastatic renal cell carcinoma in adult patients.

GNH USA supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, adhering to EU quality standards and providing reliable logistics for clinical use.

What is Axitinib used for?

Inlyta (axitinib) is used in cancers driven by vascular endothelial growth factor signaling, primarily metastatic renal cell carcinoma.

Metastatic renal cell carcinoma: improves

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →